Related Experiment Video

Updated: Sep 10, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Emerging implications of N6-methyladenosine in prostate cancer progression and treatment

Junyan Xu1, Dajun Gao2, Changjie Ren1

  • 1School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.

Cell Death Discovery
|August 19, 2025
PubMed

Insights

N6-methyladenosine (m6A) RNA modifications are crucial in prostate cancer. Targeting these m6A regulators offers promising therapeutic strategies for this common male malignancy.

Area of Science:

  • Molecular Biology
  • Oncology
  • RNA Biology

Background:

  • RNA modifications, particularly N6-methyladenosine (m6A), are prevalent across various RNA types.
  • m6A plays a significant role in the initiation and progression of diseases, including cancer.
  • Prostate cancer, a prevalent male malignancy, is increasingly recognized for its association with m6A.

Purpose of the Study:

  • To review the roles of m6A regulators (readers, writers, erasers) in prostate cancer.
  • To discuss the therapeutic potential of targeting m6A pathways in prostate cancer.
  • To explore emerging agents and technologies, like CRISPR-Cas13, for RNA-targeted prostate cancer therapy.

Main Methods:

  • Literature review of studies on m6A regulators and prostate cancer.
  • Analysis of m6A-modified mRNA and noncoding RNA involvement in prostate cancer.
  • Examination of current and future therapeutic strategies targeting m6A.

Main Results:

  • m6A regulators significantly influence prostate cancer progression.
  • m6A-modified RNAs are critical in prostate cancer development.
  • Targeting m6A pathways presents a viable therapeutic avenue for prostate cancer.

Conclusions:

  • m6A modification is a key player in prostate cancer pathogenesis.
  • Targeting m6A regulators and pathways offers novel therapeutic strategies.
  • Advanced technologies like CRISPR-Cas13 hold potential for RNA-targeted prostate cancer treatment.

More Related Videos

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

11.0K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

Related Concept Videos

Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
169
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Pre-mRNA Processing: Modification of pre-mRNA Ends01:35

Pre-mRNA Processing: Modification of pre-mRNA Ends

In eukaryotic cells, transcripts made by RNA polymerase are modified and processed before exiting the nucleus. Unprocessed RNA is called precursor mRNA or pre-mRNA to distinguish it from mature mRNA.
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a cap to the 5' end of the growing transcript. In this process, a 5' phosphate is replaced by modified guanosine that has a methyl group attached (7-methyl guanosine). This 5' cap helps...
9.8K
RNA Stability01:53

RNA Stability

Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
33.9K